racecadotril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
endopeptidase inhibitors 60 81110-73-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ecadotril
  • acetorphan
  • racecadotril
  • cadotril
  • redotil
A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
  • Molecular weight: 385.48
  • Formula: C21H23NO4S
  • CLOGP: 3.85
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.47
  • ALOGS: -5.34
  • ROTB: 11

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.12 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKDC,STK33,TEK,TTK 36
kinase-selectivity-class AXL,EIF2AK3,GRK2,PDK4 4
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1993 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rash maculo-papular 133.57 40.22 49 2654 40884 90584860
Drug reaction with eosinophilia and systemic symptoms 124.19 40.22 47 2656 42711 90583033
Acute kidney injury 113.61 40.22 86 2617 320301 90305443
Hepatic cytolysis 104.49 40.22 38 2665 30878 90594866
Cholestasis 98.55 40.22 38 2665 36261 90589483
Agranulocytosis 78.75 40.22 32 2671 34970 90590774
Aplasia 62.58 40.22 16 2687 3975 90621769
Pancytopenia 60.30 40.22 40 2663 120223 90505521
Acute generalised exanthematous pustulosis 58.29 40.22 20 2683 13683 90612061
Hepatocellular injury 56.75 40.22 24 2679 28934 90596810
Febrile bone marrow aplasia 56.63 40.22 18 2685 9720 90616024
Eosinophilia 53.77 40.22 23 2680 28510 90597234
Thrombocytopenia 50.52 40.22 45 2658 208680 90417064
Pancreatitis acute 47.99 40.22 22 2681 32093 90593651
Housebound 47.97 40.22 8 2695 238 90625506
Hypokalaemia 45.80 40.22 35 2668 131081 90494663
Granulomatous liver disease 42.90 40.22 9 2694 940 90624804

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 196.35 30.72 71 2646 26679 42591939
Alveolar lung disease 104.02 30.72 19 2698 443 42618175
Pulmonary interstitial emphysema syndrome 100.27 30.72 19 2698 544 42618074
Hepatocellular injury 99.50 30.72 42 2675 23636 42594982
Diffuse alveolar damage 76.16 30.72 20 2697 2572 42616046
Eosinophilic pneumonia 59.53 30.72 19 2698 4855 42613763
Acute kidney injury 58.18 30.72 92 2625 367245 42251373
Hyperammonaemia 58.01 30.72 21 2696 7845 42610773
Eosinophilia 57.47 30.72 32 2685 32867 42585751
Generalised oedema 50.70 30.72 23 2694 15313 42603305
Angioedema 49.89 30.72 32 2685 42445 42576173
Rash maculo-papular 48.42 30.72 30 2687 37473 42581145
Hepatic cytolysis 43.85 30.72 25 2692 26819 42591799
Enterobacter sepsis 40.69 30.72 10 2707 985 42617633
Hepatic encephalopathy 40.09 30.72 20 2697 16422 42602196
Cholestasis 39.17 30.72 25 2692 32854 42585764
Glomerular filtration rate decreased 37.26 30.72 19 2698 16332 42602286
Confusional state 35.06 30.72 48 2669 167549 42451069

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 199.79 31.44 83 5506 56644 110527066
Rash maculo-papular 162.95 31.44 78 5511 74144 110509566
Acute kidney injury 155.68 31.44 175 5414 635255 109948455
Hepatocellular injury 151.41 31.44 66 5523 50576 110533134
Hepatic cytolysis 142.95 31.44 65 5524 54988 110528722
Cholestasis 127.14 31.44 63 5526 64455 110519255
Drug reaction with eosinophilia and systemic symptoms 118.33 31.44 65 5524 82030 110501680
Alveolar lung disease 112.62 31.44 21 5568 698 110583012
Eosinophilia 109.49 31.44 55 5534 57881 110525829
Pulmonary interstitial emphysema syndrome 104.24 31.44 19 5570 556 110583154
Pancytopenia 80.80 31.44 74 5515 209539 110374171
Agranulocytosis 78.36 31.44 45 5544 61715 110521995
Angioedema 72.84 31.44 51 5538 98449 110485261
Diffuse alveolar damage 71.90 31.44 20 5569 4027 110579683
Acute generalised exanthematous pustulosis 60.70 31.44 27 5562 21637 110562073
Thrombocytopenia 60.50 31.44 81 5508 348804 110234906
Febrile bone marrow aplasia 59.53 31.44 25 5564 17440 110566270
Eosinophilic pneumonia 56.48 31.44 19 5570 7208 110576502
Hyperammonaemia 51.34 31.44 21 5568 13711 110569999
Confusional state 47.63 31.44 85 5504 468595 110115115
Generalised oedema 46.09 31.44 25 5564 30679 110553031
Housebound 44.60 31.44 9 5580 454 110583256
Hypokalaemia 40.54 31.44 48 5541 182400 110401310
Enterobacter sepsis 39.91 31.44 10 5579 1346 110582364
Aplasia 39.86 31.44 15 5574 7858 110575852
Hepatic encephalopathy 39.63 31.44 22 5567 28234 110555476
Drug ineffective 39.36 31.44 14 5575 1520526 109063184
Diarrhoea 38.15 31.44 135 5454 1139370 109444340
Pancreatitis acute 37.22 31.44 28 5561 60246 110523464
Mixed liver injury 36.89 31.44 16 5573 12063 110571647
Neutropenia 36.82 31.44 67 5522 374553 110209157
Gamma-glutamyltransferase increased 34.60 31.44 27 5562 61282 110522428
General physical condition abnormal 33.20 31.44 13 5576 7577 110576133
Distal intestinal obstruction syndrome 32.38 31.44 8 5581 1017 110582693

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07XA04 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
OTHER ANTIDIARRHEALS
Other antidiarrheals
MeSH PA D000930 Antidiarrheals
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D011480 Protease Inhibitors

Related Drugs by ATC class:

A07XA Other antidiarrheals 1 drug
crofelemer

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute diarrhea indication 409966000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Neprilysin Enzyme INHIBITOR IC50 9 CHEMBL KEGG DRUG
Endothelin-converting enzyme 1 Enzyme IC50 8.10 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 6.50 CHEMBL
Puromycin-sensitive aminopeptidase Enzyme IC50 4.24 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 6.38 CHEMBL
Neprilysin Enzyme IC50 8.32 CHEMBL
Neprilysin Enzyme IC50 8.40 CHEMBL
Neprilysin Enzyme IC50 8.21 CHEMBL
Thermolysin Enzyme IC50 5.02 CHEMBL
Beta-lactamase NDM-1 Enzyme IC50 5.75 CHEMBL

External reference:

IDSource
4025231 VUID
N0000179029 NUI
D08464 KEGG_DRUG
112573-73-6 SECONDARY_CAS_RN
16738 RXNORM
C0050461 UMLSCUI
CHEBI:750459 CHEBI
TIO PDB_CHEM_ID
CHEMBL2103772 ChEMBL_ID
CHEMBL1516410 ChEMBL_ID
DB11696 DRUGBANK_ID
C049331 MESH_SUPPLEMENTAL_RECORD_UI
107751 PUBCHEM_CID
11654 IUPHAR_LIGAND_ID
7378 INN_ID
76K53XP4TO UNII
DB08626 DRUGBANK_ID
C0039945 UMLSCUI
CHEMBL10247 ChEMBL_ID
6896 INN_ID
76721-89-6 SECONDARY_CAS_RN
3132 PUBCHEM_CID
5278 IUPHAR_LIGAND_ID
4025231 VANDF
D015244 MESH_DESCRIPTOR_UI
B79L7B5X3Z UNII
006079 NDDF
699272003 SNOMEDCT_US
714679008 SNOMEDCT_US
785287002 SNOMEDCT_US
CHEBI:9568 CHEBI
76K53XP4TO INXIGHT DRUGS

Pharmaceutical products:

None